Konference: 2015 20th Congress of the European Hematology Association - účast ČR
Kategorie: Myelodysplastický syndrom
Téma: ePoster
Číslo abstraktu: E1197
Autoři: Ing. Michaela Dostálová-Merkerová, Ph.D.; Ing. Zdeněk Krejčík, Ph.D.; Mgr. Andrea Hruštincová (Mrhálková); Ing. Eva Ratajová (Otáhalová); Mgr. Monika Běličková; prof. MUDr. Jaroslav Čermák, CSc.
Background
Myelodysplastic syndromes (MDS) represent a wide range of
hematopoietic stem cell disorders characterized by ineffective
hematopoiesis, peripheral blood cytopenias, and a tendency to
evolve into acute myeloid leukemia. MicroRNAs (miRNAs) are short
endogenous non-coding RNA molecules that play an essential role in
the regulation of gene expression at post-transcriptional levels.
Existence of miRNAs has been recognized not only in the
intracellular environment but it has recently been shown that these
molecules are also present in a wide variety of body fluids,
including blood plasma. Cell free miRNAs (referred to as
circulating miRNAs) have been repeatedly proved to function as new
promising semi-invasive diagnostic markers of various types of
cancer but only little information is known about their
deregulation in MDS.
Aims
In this study, we focus on alteration of miRNA levels circulating
in plasma of MDS patients with the emphasis on differences between
low and high risk disease.
Methods
Peripheral blood plasma was collected from 40 patients with
untreated primary MDS and from 10 healthy, age-matched donors with
no medical history. Written informed consent was obtained from all
tested subjects in accordance with the Institutional Review Board.
Total RNA was extracted from plasma using Qiagen miRNeasy mini kit.
Agilent Human miRNA Microarrays were used to assess the amount of
2,006 human miRNAs in blood plasma from 13 MDS patients and 6
healthy donors. The microarray results were confirmed in the
complete set of samples by RT-qPCR.
Results
Statistical analyses identified significant differences in a plasma
profile of circulating miRNAs between different study groups. In
MDS, 19 down-regulated and 25 up-regulated miRNAs were detected
compared to healthy controls. Some hematopoiesis and/or
oncology-associated miRNAs were found in the list of deregulated
molecules, e.g. down-regulation of miR-92a-3p, miR-142-3p/5p,
miR-320a/b/d/e, and miR-451a, and up-regulation of miR-150-5p,
miR-188-5p, and miR-548q. Low-risk and high-risk groups of patients
significantly differed in levels of several miRNAs, namely in
reduction of miR-185-5p and miR-4306 and elevation of miR-548q,
miR-623, miR-4707-5p, miR-4721, and miR-4739 in high-risk
patients.
Summary
Expression profiling of plasma miRNAs in patients with MDS revealed
several miRNAs with altered levels gradually changing within the
disease progression, suggesting that circulating miRNAs may be new
candidate molecular markers for monitoring of the disease.
This work was supported by the grant NT13847-4 from the Ministry of Health of the Czech Republic.
Keyword(s): Microarray analysis, Myelodysplasia,
Plasma
Datum přednesení příspěvku: 12. 6. 2015